A single-site, double-blind, placebo-controlled cross-over trial examining the safety and efficacy of olanzapine taken daily for the prevention of episodic migraine
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2011
At a glance
- Drugs Olanzapine (Primary)
- Indications Migraine with aura; Migraine without aura
- Focus Therapeutic Use
- 23 Aug 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 13 Jul 2011 Planned end date (1 Jun 2006) added as reported by ClinicalTrials.gov.
- 29 Oct 2005 New trial record.